JPWO2019234694A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019234694A5
JPWO2019234694A5 JP2020566845A JP2020566845A JPWO2019234694A5 JP WO2019234694 A5 JPWO2019234694 A5 JP WO2019234694A5 JP 2020566845 A JP2020566845 A JP 2020566845A JP 2020566845 A JP2020566845 A JP 2020566845A JP WO2019234694 A5 JPWO2019234694 A5 JP WO2019234694A5
Authority
JP
Japan
Prior art keywords
dose
adc
here
patient
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020566845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526525A (ja
JP2021526525A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/054748 external-priority patent/WO2019234694A2/en
Publication of JP2021526525A publication Critical patent/JP2021526525A/ja
Publication of JPWO2019234694A5 publication Critical patent/JPWO2019234694A5/ja
Publication of JP2021526525A5 publication Critical patent/JP2021526525A5/ja
Priority to JP2024095931A priority Critical patent/JP2024154433A/ja
Pending legal-status Critical Current

Links

JP2020566845A 2018-06-07 2019-06-07 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法 Pending JP2021526525A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024095931A JP2024154433A (ja) 2018-06-07 2024-06-13 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862682154P 2018-06-07 2018-06-07
US62/682,154 2018-06-07
US201962841702P 2019-05-01 2019-05-01
US62/841,702 2019-05-01
PCT/IB2019/054748 WO2019234694A2 (en) 2018-06-07 2019-06-07 Therapeutic methods using antibody drug conjugates (adcs)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024095931A Division JP2024154433A (ja) 2018-06-07 2024-06-13 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法

Publications (3)

Publication Number Publication Date
JP2021526525A JP2021526525A (ja) 2021-10-07
JPWO2019234694A5 true JPWO2019234694A5 (https=) 2022-06-14
JP2021526525A5 JP2021526525A5 (https=) 2022-06-14

Family

ID=68769968

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566845A Pending JP2021526525A (ja) 2018-06-07 2019-06-07 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法
JP2024095931A Pending JP2024154433A (ja) 2018-06-07 2024-06-13 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024095931A Pending JP2024154433A (ja) 2018-06-07 2024-06-13 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法

Country Status (7)

Country Link
US (2) US20210283267A1 (https=)
EP (1) EP3801635A4 (https=)
JP (2) JP2021526525A (https=)
CN (1) CN112566671A (https=)
AU (1) AU2019283654A1 (https=)
CA (1) CA3101943A1 (https=)
WO (1) WO2019234694A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3079215A1 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
CN121555430A (zh) 2018-05-11 2026-02-24 比姆医疗股份有限公司 使用可编程碱基编辑器系统取代病原性氨基酸的方法
EP3959242A4 (en) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
EP3958899A4 (en) * 2019-04-24 2023-08-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND THEIR USES
JP2022529727A (ja) * 2019-04-24 2022-06-23 マジェンタ セラピューティクス インコーポレイテッド Ａｎｔｉ－ｃｄ１１７ とその使用
EP3958909A4 (en) * 2019-04-24 2024-01-10 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF
GB202004263D0 (en) * 2020-03-24 2020-05-06 Autolus Ltd Antibody conjugate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304721A1 (en) * 2005-09-07 2009-12-10 Medlmmune, Inc Toxin conjugated eph receptor antibodies
WO2008070593A2 (en) * 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
AR086044A1 (es) * 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
FI3656869T4 (fi) * 2014-08-26 2025-06-04 Univ Leland Stanford Junior Kantasolujen siirrostaminen kantasoluihin kohdentuvan aineen ja immunoregulatorista signaalia moduloivan aineen yhdistelmän kanssa
JP6668345B2 (ja) * 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
HK1249534A1 (zh) * 2015-04-06 2018-11-02 哈佛大学校长及研究员协会 用於非清髓性预处理的组合物和方法
CA2984892A1 (en) * 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
EP3222292A1 (en) * 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
US10464969B2 (en) * 2016-05-05 2019-11-05 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
BR112018076306A2 (pt) * 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+
CA3045592A1 (en) * 2016-12-21 2018-06-28 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
JP2020519640A (ja) * 2017-05-17 2020-07-02 イミュノジェン， インコーポレイテッド 抗ｃｄ３３イムノコンジュゲート投与計画

Similar Documents

Publication Publication Date Title
JP2021526525A5 (https=)
Shaw et al. Recent advances in trichosanthin, a ribosome-inactivating protein with multiple pharmacological properties
CN102458479B (zh) 识别IgG结合位点的方法
ES2551439T5 (es) Fragmentos Fab de anticuerpos modificados
Steiner et al. Long-term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single-center study
TR201810005T4 (tr) Il-4 ve/veya ıl-13 bağlayan antikorlar ve bunların kullanımı.
JP2023126877A (ja) 組換えウリカーゼ酵素
JPWO2019234694A5 (https=)
JP5716205B2 (ja) グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
JP2021503441A (ja) Ｐｅｇ化されたカルフィルゾミブ化合物の安定組成物
JPH05507065A (ja) 抗ウイルス性組成物及びその使用方法
Niemeyer et al. Long-term safety, tolerability and efficacy of daclizumab (Zenapax®) in a two-dose regimen in liver transplant recipients
US20250381280A1 (en) Nanoplatform for targeting inflammatory macrophages, and composition containing same for preventing or treating inflammatory diseases
EP2746268B1 (en) Method for chemical synthesis of antrocin
US20260027116A1 (en) Methods of Treating Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
ES2982564T3 (es) Análogos de nucleósidos bicíclicos y monocíclicos para el tratamiento de la hepatitis E
US20060281820A1 (en) Lfa-1 inhibitors and use thereof
CN103554187B (zh) 铂类配合物、由该铂类化合物制得的蛋白质复合物及其制备方法
CN1040178C (zh) 补体抑制剂用于制备促进移植存活或消除排斥反应的药物
Dymock Skin diseases associated with renal transplantation
US10988429B2 (en) Quinochalcone compound and uses thereof for treating cancer or inflammation
WO2000067792A1 (fr) Anticorps monoclonal dirige contre les cellules de carcinome renal humain
CN116375789B (zh) 一种抗肿瘤化合物、其制备方法、药物组合物及应用
CN121248804B (zh) 一种骨靶向蛋白偶联螯合剂及其制备方法和应用
CA1175421A (en) TREATMENT OF MALIGNANT TUMORS WITH 2-.beta.-D- RIBOFURANOSYLTHIAZOLE-4-CARBOXAMIDE AND RELATED COMPOUNDS